Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pfs25-IMX313 + Matrix-M1
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Pfs25-IMX313 + Matrix-M1** is a combination vaccine candidate for malaria prevention. It consists of the recombinant protein-nanoparticle vaccine Pfs25-IMX313 (based on the *Plasmodium falciparum* sexual-stage antigen Pfs25 fused to the IMX313 oligomerization domain) and the saponin-based adjuvant Matrix-M1. The primary mechanism of action is to induce an immune response that blocks transmission of malaria parasites from humans to mosquitoes, thereby reducing disease spread. The vaccine is administered intramuscularly in multiple doses and has been evaluated primarily for safety and immunogenicity in healthy adults[5][7][9].
- Other names
- Pfs25-IMX313/Matrix-MPfs25-IMX313 in Matrix-M1 adjuvantPfs-25-IMX313 in Matrix-M1 adjuvantPfs 25-IMX313 in Matrix-M1 adjuvant
02
Targets
Pfs25
Beyond the preview
Go deeper on Pfs25-IMX313 + Matrix-M1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pfs25-IMX313 + Matrix-M1.